Lane A
Independent Research Economist, Auckland, New Zealand.
Pharmacoeconomics. 1996 Mar;9(3):231-45. doi: 10.2165/00019053-199609030-00005.
The burden of illness of osteoporosis in New Zealand is substantial. Prevalence estimates based on international research suggest that up to 30% of postmenopausal women may have osteoporosis. The projected increase in population of women aged >or= 60 years suggests that the burden of illness associated with osteoporosis will escalate. Currently, cost estimates in New Zealand for specific procedures are severely limited by the absence of a comprehensive, nationwide, case-mix system of costing. In this analysis, first-year total direct costs of hospitalisation, recovery and residential care associated with osteoporotic hip fractures, assuming an annual incidence of 1537.63 such fractures in New Zealand women aged > or = 60 years, were estimated at $NZ41,684,460 [1995 dollars ($NZ1 = $US0.65 in 1995)]. Second-year costs were $NZ24,952,895. The combined total over 2 years post-hip fracture was estimated to be $NZ66,637,355. Annual non-hip fracture costs for women aged > or = 45 years were estimated at $NZ4 401 248. Pharmacotherapy data for the treatment of osteoporosis indicate that the societal costs of treating the diagnosed condition for men and women in New Zealand are $NZ3 385 590 per year (1995 dollars).
骨质疏松症在新西兰造成的疾病负担相当大。基于国际研究的患病率估计表明,高达30%的绝经后女性可能患有骨质疏松症。预计60岁及以上女性人口的增加表明,与骨质疏松症相关的疾病负担将会加重。目前,由于缺乏全面的、全国性的病例组合成本核算系统,新西兰特定医疗程序的成本估计受到严重限制。在本分析中,假设新西兰60岁及以上女性髋部骨质疏松性骨折的年发病率为1537.63例,估计与髋部骨质疏松性骨折相关的住院、康复和住院护理的第一年总直接成本为41684460新西兰元[1995年美元(1995年1新西兰元 = 0.65美元)]。第二年的成本为24952895新西兰元。髋部骨折后两年的总费用估计为66637355新西兰元。45岁及以上女性每年非髋部骨折的成本估计为4401248新西兰元。骨质疏松症治疗的药物治疗数据表明,新西兰男女治疗确诊疾病的社会成本为每年3385590新西兰元(1995年美元)。